Spyre Therapeutics, Inc.
SYRE
$28.40
-$0.26-0.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 12.71% | -3.55% | |||
| Gross Profit | -12.71% | 3.55% | |||
| SG&A Expenses | -1.26% | -1.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.54% | -3.05% | |||
| Operating Income | -9.54% | 3.05% | |||
| Income Before Tax | 69.54% | 18.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.54% | 17.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.54% | 17.99% | |||
| EBIT | -9.54% | 3.05% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 69.57% | 18.07% | |||
| Normalized Basic EPS | 76.09% | -4.18% | |||
| EPS Diluted | 69.57% | 18.07% | |||
| Normalized Diluted EPS | 76.09% | -4.18% | |||
| Average Basic Shares Outstanding | 0.13% | 0.11% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||